Skip to main content
. 2020 Sep 18;20(5):255. doi: 10.3892/ol.2020.12118

Figure 1.

Figure 1.

Pan-cancer analysis of SCGB2A1 mRNA expression in different databases. (A) SCGB2A1 mRNA expression in different tumor types compared with normal samples according to different analyses of the Oncomine database. The number represents the count of significant unique analyses. Red represents overexpression of the gene and blue represents low expression of the gene. All P<0.0001 cancer vs. normal. (B) mRNA expression levels of SCGB2A1 in different tumor types analyzed by TIMER based on TCGA. Red indicates tumor tissues and blue indicates normal tissues. *P<0.05, **P<0.01 and ***P<0.001. SCGB2A1, secretoglobin family 2A member 1; TIMER, Tumor Immune Estimation Resource; TCGA, The Cancer Genome Atlas; BRCA, breast invasive carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; HNSC, head and neck cancer; KIRC, kidney renal clear cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma.